» Articles » PMID: 36615411

Traditional Machine and Deep Learning for Predicting Toxicity Endpoints

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Jan 8
PMID 36615411
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular structure property modeling is an increasingly important tool for predicting compounds with desired properties due to the expensive and resource-intensive nature and the problem of toxicity-related attrition in late phases during drug discovery and development. Lately, the interest for applying deep learning techniques has increased considerably. This investigation compares the traditional physico-chemical descriptor and machine learning-based approaches through autoencoder generated descriptors to two different descriptor-free, Simplified Molecular Input Line Entry System (SMILES) based, deep learning architectures of Bidirectional Encoder Representations from Transformers (BERT) type using the Mondrian aggregated conformal prediction method as overarching framework. The results show for the binary CATMoS non-toxic and very-toxic datasets that for the former, almost equally balanced, dataset all methods perform equally well while for the latter dataset, with an 11-fold difference between the two classes, the MolBERT model based on a large pre-trained network performs somewhat better compared to the rest with high efficiency for both classes (0.93-0.94) as well as high values for sensitivity, specificity and balanced accuracy (0.86-0.87). The descriptor-free, SMILES-based, deep learning BERT architectures seem capable of producing well-balanced predictive models with defined applicability domains. This work also demonstrates that the class imbalance problem is gracefully handled through the use of Mondrian conformal prediction without the use of over- and/or under-sampling, weighting of classes or cost-sensitive methods.

Citing Articles

CPSign: conformal prediction for cheminformatics modeling.

Arvidsson McShane S, Norinder U, Alvarsson J, Ahlberg E, Carlsson L, Spjuth O J Cheminform. 2024; 16(1):75.

PMID: 38943219 PMC: 11214261. DOI: 10.1186/s13321-024-00870-9.

References
1.
Hwang T, Carpenter D, Lauffenburger J, Wang B, Franklin J, Kesselheim A . Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med. 2016; 176(12):1826-1833. DOI: 10.1001/jamainternmed.2016.6008. View

2.
Schaduangrat N, Lampa S, Simeon S, Gleeson M, Spjuth O, Nantasenamat C . Towards reproducible computational drug discovery. J Cheminform. 2021; 12(1):9. PMC: 6988305. DOI: 10.1186/s13321-020-0408-x. View

3.
Maziarka L, Majchrowski D, Danel T, Gainski P, Tabor J, Podolak I . Relative molecule self-attention transformer. J Cheminform. 2024; 16(1):3. PMC: 10765783. DOI: 10.1186/s13321-023-00789-7. View

4.
DiMasi J, Grabowski H, Hansen R . Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20-33. DOI: 10.1016/j.jhealeco.2016.01.012. View

5.
Cox P, Gupta R . Contemporary Computational Applications and Tools in Drug Discovery. ACS Med Chem Lett. 2022; 13(7):1016-1029. PMC: 9290028. DOI: 10.1021/acsmedchemlett.1c00662. View